文献リスト

1) Thal LJ, Carta A, Doody R, et al. Prevention protocols for Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord. 1997; 11 Suppl 3: 46-9

2) Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999; 56: 303-8

3) Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004; 256: 183-94

4) Gauthier S, Reisberg B, Zaudig M, et al. Mild cognitive impairment. Lancet. 2006; 367: 1262-70

5) Bruscoli M, Lovestone S. Is MCI really just early dementia？ A systematic review of conversion studies. Int Psychogeriatr. 2004; 16: 129-40

6) Ravaglia G, Forti P, Maioli F, et al. Conversion of mild cognitive impairment to dementia: predictive role of mild cognitive impairment subtypes and vascular risk factors. Dement Geriatr Cogn Disord. 2006; 21: 51-8

7) Palmer K, Backman L, Winblad B, et al. Mild cognitive impairment in the general population: occurrence and progression to Alzheimer disease. Am J Geriatr Psychiatry. 2008; 16: 603-11

8) Manly JJ, Tang MX, Schupf N, et al. Frequency and course of mild cognitive impairment in a multiethnic community. Ann Neurol. 2008; 63: 494-506

9) Fischer P, Jungwirth S, Zehetmayer S. Conversion from subtypes of mild cognitive impairment to Alzheimer dementia. Neurology. 2007; 68: 288-91

10) Visser PJ, Kester A, Jolles J, et al. Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology. 2006; 67: 1201-7

11) Maioli F, Coveri M, Pagni P, et al. Conversion of mild cognitive impairment to dementia in elderly subjects: a preliminary study in a memory and cognitive disorder unit. Arch Gerontol Geriatr. 2007; 44 Suppl 1: 233-41

12) Saito Y, Murayama S. Neuropathology of mild cognitive impairment. Neuropathology. 2007; 27: 578-84

13) Tyas SL, Salazar JC, Snowdon DA, et al. Transitions to mild cognitive impairments, dementia, and death: findings from the Nun Study. Am J Epidemiol. 2007; 165: 1231-8

14) Kryscio RJ, Schmitt FA, Salazar JC, et al. Risk factors for transitions from normal to mild cognitive impairment and dementia. Neurology. 2006; 66: 828-32

15) Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002; 297: 353-6

16) van der Flier WM, Pijnenburg YA, et al. Distribution of APOE genotypes in a memory clinic cohort. Dement Geriatr Cogn Disord. 2008; 25: 433-8

17) Ewers M, Zhong Z, Burger K, et al. Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Brain. 2008; 131(Pt 5): 1252-8

18) Bertram L, McQueen MB, Mullin K, et al. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007; 39: 17-23

19) Lu T, Pan Y, Kao SY, et al. Gene regulation and DNA damage in the ageing human brain. Nature. 2004; 429: 883-91

20) Miller JA, Oldham MC, Geschwind DH. A systems level analysis of transcriptional changes in Alzheimer's disease and normal aging. J Neurosci. 2008; 28: 1410-20

21) Hellstrom-Lindahl E, Ravid R, Nordberg A. Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: inverse correlation with A beta levels. Neurobiol Aging. 2008; 29: 210-21

22) Kern A, Roempp B, Prager K, et al. Down-regulation of endogenous amyloid precursor protein processing due to cellular aging. J Biol Chem. 2006; 281: 2405-13

23) Schmitt FA, Scheff SW, et al. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology. 2005; 64: 1152-6

24) Williams TI, Lynn BC, Markesbery WR, et al. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in mild cognitive impairment and ear-ly Alzheimer's disease. Neurobiol Aging. 2006; 27: 1094-9

25) Reitz C, Tang MX, Manly J, et al. Hypertension and the risk of mild cognitive impairment. Arch Neurol. 2007; 64: 1734-40

26) Schrader J, Luders S, Diener HC, et al. Effects of Long-Term Antihypertensive Therapy with Losartan on Blood Pressure and Cognitive Function in Patients with Essential Hypertension and Other Cerebrovascular Risk Factors (AWARE Observational Study. Med Klin (Munich). 2008; 103: 491-9

27) Wang J, Ho L, Chen L, et al. Valsartan lowers brainβ-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest. 2007; 117: 3393-402

28) Anstey KJ, Lipnicki DM, Low LF. et al. Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospec-tive studies with meta-analysis. Am J Geriatr Psychiatry. 2008; 16: 343-54

29) Solomon A, Kareholt I, Ngandu T, et al. Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology. 2007; 68: 751-6

30) Reitz C, Tang MX, Manly J, et al. Plasma lipid levels in the elderly are not associated with the risk of mild cognitive impairment. Dement Geriatr Cogn Disord. 2008; 25: 232-7

31) Sparks DL, Kryscio RJ, Sabbagh MN, et al. Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr Alzheimer Res. 2008; 5: 416-21

32) Luchsinger JA, Reitz C, Patel B, et al. Relation of diabetes to mild cognitive impairment. Arch Neurol. 2007; 64: 570-5

33) Roberts RO, Geda YE, Knopman DS, et al. Association of duration and severity of diabetes mellitus with mild cognitive impairment. Arch Neurol. 2008; 65: 1066-73

34) Ronnemaa E, Zethelius B, Sundelof J, et al. Impaired insulin secretion increases the risk of Alzheimer disease. Neurology. 2008; 71: 1065-71

35) Ho L, Qin W, Pompl PN, et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J. 2004; 18: 902-4

36) Forti P, Maioli F, Pisacane N, et al. Atrial fibrillation and risk of dementia in non-demented elderly subjects with and without mild cognitive impairment (MCI). Arch Gerontol Geriatr. 2007; 44 Suppl 1: 155-65

37) Kukar T, Prescott S, Eriksen JL, et al. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci. 2007; 8: 54

38) Gomez-Isla T, Blesa R, Boada M, et al. A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study. Alzheimer Dis Assoc Disord. 2008; 22: 21-9

39) Kukar T, Murphy MP, Eriksen JL, et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Aβ42 production. Nat Med. 2005; 11: 545-50

40) Thal LJ, Ferris SH, Kirby L, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. 2005; 30: 1204-15

41) Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004; 291: 2947-58

42) Hogervorst E, Huppert F, Matthews FE, et al. Thyroid function and cognitive decline in the MRC Cognitive Function and Ageing Study. Psychoneuroendocrinology. 2008; 33: 1013-22

43) Tan ZS, Beiser A, Vasan RS, et al. Thyroid function and the risk of Alzheimer disease: the Framingham Study. Arch Intern Med. 2008; 168: 1514-20

44) Moffat SD, Zonderman AB, Metter EJ, et al. Free testosterone and risk for Alzheimer disease in older men. Neurology. 2004; 62: 188-93

45) Rosario ER, Chang L, Stanczyk FZ, et al. Age-related testosterone depletion and the development of Alzheimer disease. JAMA. 2004; 292: 1431-2

46) Rosario ER, Carroll JC, Oddo S, et al. Androgens regulate the development of neuropathology in a triple transgenic mouse model of Alzheimer's disease. J Neurosci. 2006; 26: 13384-9

47) Geda YE, Knopman DS, Mrazek DA, et al. Depression, apolipoprotein E genotype, and the incidence of mild cognitive impairment: a prospective cohort study. Arch Neurol. 2006; 63: 435-40

48) Barnes DE, Alexopoulos GS, Lopez OL, et al. Depressive symptoms, vascular disease, and mild cognitive impairment: findings from the Cardiovascular Health Study. Arch Gen Psychiatry. 2006; 63: 273-9

49) Palmer K, Berger AK, Monastero R, et al. Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology. 2007; 68: 1596-602

50) Komulainen P, Lakka TA, Kivipelto M, et al. Metabolic syndrome and cognitive function: a population-based follow-up study in elderly women. Dement Geriatr Cogn Disord. 2007; 23: 29-34

51) Kivipelto M, Ngandu T, Fratiglioni L, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol. 2005; 62: 1556-60

52) Patel NV, Gordon MN, Connor KE, et al. Caloric restriction attenuates Aβ-deposition in Alzheimer transgenic models. Neurobiol Aging. 2005; 26: 995-1000

53) Eskelinen MH, Ngandu T, Helkala EL, et al. Fat intake at midlife and cognitive impairment later in life: a population-based CAIDE study. Int J Geriatr Psychiatry. 2008; 23: 741-7

54) Vedin I, Cederholm T, Freund Levi Y, et al. Effects of docosahexaenoic acid-rich n-3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. Am J Clin Nutr. 2008; 87: 1616-22

55) van de Rest O, Geleijnse JM, Kok FJ, et al. Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial. Neurology. 2008; 71: 430-8

56) Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloidβ oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 2005; 280: 5892-901

57) Luchsinger JA, Tang MX, Siddiqui M, et al. Alcohol intake and risk of dementia. J Am Geriatr Soc. 2004; 52: 540-6

58) Wang J, Ho L, Zhao W, et al. Grape-derived polyphenolics prevent Aβ oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease. J Neurosci. 2008; 28: 6388-92

59) Rezai-Zadeh K, Shytle D, et al. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci. 2005; 25: 8807-14

60) Dunn JE, Weintraub S, Stoddard AM, et al. Serum alpha-tocopherol, concurrent and past vitamin E intake, and mild cognitive impairment. Neurology. 2007; 68: 670-6

61) Isaac MG, Quinn R, Tabet N. Vitamin E for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev. 2008; (3): CD002854

62) Fioravanti M, Ferrario E, Massaia M, et al. Low folate levels in the cognitive decline of elderly patients and the efficacy of folate as a treatment for improving memory deficits. Arch Gerontol Geriatr. 1998; 26: 1-13

63) Arendash GW, Schleif W, Rezai-Zadeh K, et al. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain β-amyloid production. Neuroscience. 2006; 142: 941-52

64) Ritchie K, Carrere I, de Mendonca A, et al. The neuroprotective effects of caffeine: a prospective population study (the Three City Study). Neurology. 2007; 69: 536-45

65) Matsubara E, Bryant-Thomas T, Pacheco Quinto J, et al. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J Neurochem. 2003; 85: 1101-8

66) Furio AM, Brusco LI, Cardinali DP. Possible therapeutic value of melatonin in mild cognitive impairment: a retrospective study. J Pineal Res. 2007; 43: 404-9

67) Ngandu T, Helkala EL, Soininen H, et al. Alcohol drinking and cognitive functions: findings from the Cardiovascular Risk Factors Aging and Dementia (CAIDE) Study. Dement Geriatr Cogn Disord. 2007; 23: 140-9

68) Stampfer MJ, Kang JH, Chen J, et al. Effects of moderate alcohol consumption on cognitive function in women. N Engl J Med. 2005; 352: 245-53

69) Liu Q, Zhang J, Zhu H, et al. Dissecting the signaling pathway of nicotine-mediated neuroprotection in a mouse Alzheimer disease model. FASEB J. 2007; 21: 61-73

70) Sabia S, Marmot M, Dufouil C, et al. Smoking history and cognitive function in middle age from the Whitehall II study. Arch Intern Med. 2008; 168: 1165-73

71) Anstey KJ, von Sanden C, Salim A, et al. Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. Am J Epidemiol. 2007; 166: 367-78

72) Kuhlmann S, Piel M, Wolf OT. Impaired memory retrieval after psychosocial stress in healthy young men. J Neurosci. 2005; 25: 2977-82

73) Jeong YH, Park CH, Yoo J, et al. Chronic stress accelerates learning and memory impairments and increases amyloid deposition in APPV717I-CT100 transgenic mice, an Alzheimer's disease model. FASEB J. 2006; 20: 729-31

74) Adlard PA, Perreau VM, Pop V, et al. Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J Neurosci. 2005; 25: 4217-21

75) Rovio S, Kareholt I, Helkala EL, et al. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol. 2005; 4: 705-11

76) Rovio S, Kareholt I, Viitanen M, et al. Work-related physical activity and the risk of dementia and Alzheimer's disease. Int J Geriatr Psychiatry. 2007; 22: 874-82

77) Hansson O, Zetterberg H, Buchhave P. Prediction of Alzheimer's disease using the CSF Aβ42/Aβ40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord. 2007; 23: 316-20

78) Kawarabayashi T, Shoji M. Plasma biomarkers of Alzheimer's disease. Curr Opin Psychiatry. 2008; 21: 260-7

79) Graff-Radford NR, Crook JE, Lucas J, et al. Association of low plasma Aβ42/Aβ40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol. 2007; 64: 354-62

80) Devanand DP, Pradhaban G, Liu X. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology. 2007; 68: 828-36

81) Pike KE, Savage G, Villemagne VL, et al. β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007; 130: 2837-44

82) Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain. 2008; 131: 665-80

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp